
PROPOSED PLACEMENT OF 562,500,000 NEW ORDINARY SHARES IN THE SHARE CAPITAL OF OUE LIPPO HEALTHCARE LIMITED AT THE ISSUE PRICE OF S\$0.14 FOR EACH NEW SHARE

- RECEIPT OF LISTING AND QUOTATION NOTICE

The Board of Directors of OUE Lippo Healthcare Limited (the "**Company**", and together with its subsidiaries the "**Group**") (the "**Board**") refers to the announcement of the Company dated 10 January 2018 (the "**10 January Announcement**") in relation to the issuance of 562,500,000 new ordinary shares in the share capital of the Company pursuant to a placement agreement entered into with Brownny Healthcare Pte Ltd (the "**Subscriber**").

Capitalised terms used herein shall have the definitions ascribed to them in the 10 January Announcement, unless otherwise stated or the context otherwise requires.

Further to the 10 January Announcement, the Board is pleased to announce that the Company has, on 9 February 2018, received the listing and quotation notice from the SGX-ST for the listing and quotation of the Placement Shares on the Catalist Board, subject to compliance with the SGX-ST listing requirements (the "**LQN**").

The Placement Shares have to be placed out within seven (7) market days from the date of the LQN.

The LQN is not to be taken as an indication of the merits of the proposed Placement, the Placement Shares, the Group and their securities.

The Company will make further announcement(s) to update shareholders on the Placement as and when appropriate.

By Order of the Board,

OUE Lippo Healthcare Limited

Dr. Wong Weng Hong

Chief Executive Officer and Executive Director

12 February 2018

*This announcement has been prepared by OUE Lippo Healthcare Limited (formerly known as International Healthway Corporation Limited) (the "**Company**") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of*

this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809 **T:** +65 6578 9188 **F:** 64794647

www.ouelh.com